Oncodesign, a pioneer in precision medicine

A philosophy rooted in technological innovation

Since 1995, Oncodesign has been innovating to discover new therapies for cancers and diseases with no known treatment.

Scientific and commercial support for drug discovery

oncodesign-service

Integrated services in drug discovery | Services BU

State-of-the-art expertise available throughout the whole process, from hit finding to the IND, so you can discover and test your innovative therapies

Des-approches-technologiques-innovantes-valorisées-par-la-BU-Biotech

Innovative technological approaches | Biotech BU

Innovative technologies and partnerships so your therapeutic programs can make progress

intelligence-artificielle

Artificial Intelligence tools | AI BU

Hybrid AI and Drug Discovery expertise for a faster and more reliable drug candidate search process

Abstract molecule model. Scientific research in molecular chemis

Homing : a preclinical co-development program for your molecule

Combined expertise to speed up your oncology and immuno-oncology research & development programs

schema_technologies_simplifie

Our innovation technologies optimize your drug discovery programs to make them faster and more reliable

For more than 25 years, Oncodesign has been investing in precision medicine research technologies, which are essential from the very first stages of the Drug Discovery process. Our technology modules allow a continuum from molecule to patient, with the goal of discovering new treatments for patients with no therapeutic options.

Science within easy reach!

Science within easy reach!

Receive our monthly general newsletters or our biannual shareholder newsletter.

Our latest resources

Our latest resources

04/11/2021

Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia

Read more
21/10/2021

Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.

Read more
20/10/2021

[Webinars] Radiopharmaceutics, COVID-19, Microbiome… join us this fall during a webinar

Read more